enquiry@dsij.in |+91 9240904920
SENSEX512.34
82,104.790.63%

Park Medi World targets expansion-led growth as new hospitals temporarily weigh on margins

Park Medi World Ltd.

Broker Recommendation:

BUY

Broker: Choice Institutional Equities

16 Nov 2026

Sector: Healthcare

Original PDF
Reco. Price

₹255

CMP

₹244.95

Target

₹350

Upside

37.25%

Investment View and Valuation

Choice Institutional Equities, in its November 16, 2026 Q2FY27 result update on Park Medi World Ltd, retained its BUY rating and Rs 350 target price. The broker views the company as positioned for sustained growth through a cluster-led expansion strategy, a rising contribution from higher-value specialties, a shift towards private-pay patients and continued ARPOB growth.

Choice expects near-term margin pressure from new-hospital ramp-up and one-off costs to normalise over the next few quarters. Its target price is based on rolling valuation forward to 18 times average FY28E and FY29E EV/EBITDA.

Q2FY27 Financial Performance

Park Medi World's Q2FY27 revenue was Rs 511 crore, up 24.6 per cent YoY and 7.4 per cent QoQ, marginally above Choice's Rs 503 crore estimate. However, EBITDA was 22.9 per cent below the broker's estimate and fell 9.8 per cent YoY and 19.3 per cent QoQ. EBITDA margin contracted 758 basis points YoY and 660 basis points QoQ to 19.9 per cent.

PAT of Rs 52 crore was 39.0 per cent below Choice's estimate, declining 29.2 per cent YoY and 36.8 per cent QoQ, while PAT margin was 10.2 per cent. Margin pressure reflected higher patient-service costs, including food and beverage expenses, as well as greater consumption of high-value medicines and implants associated with a richer specialty mix.

Metric Q2FY27 actual Estimate / comparison
Revenue Rs 511 crore 24.6% YoY; 7.4% QoQ; Rs 503 crore estimate
EBITDA Rs 102 crore 22.9% below estimate; down 9.8% YoY and 19.3% QoQ
EBITDA margin 19.9% Down 758 bps YoY and 660 bps QoQ
PAT Rs 52 crore 39.0% below estimate; down 29.2% YoY and 36.8% QoQ
PAT margin 10.2% —

Operating Performance and Specialty Mix

Management said patient volumes and ramp-up at recently commissioned hospitals supported revenue. IPD and OPD volumes increased 31 per cent and 29 per cent YoY, respectively. ARPOB rose 13 per cent YoY to Rs 30,646 and average length of stay improved to 5.4 days. High-end tertiary and quaternary specialties accounted for 64 per cent of revenue.

Network occupancy declined to 56 per cent from 69 per cent YoY because of capacity additions. The mature 14-hospital network maintained an EBITDA margin of about 26 per cent, while three newly commissioned hospitals generated Rs 72 crore revenue in H1FY27 and an EBITDA loss of Rs 6 crore.

Vriddhi_Growth.webp

Participating in Future Growth Themes

Structural changes and innovation can create long-term investment opportunities. DSIJ's Vriddhi Growth focuses on businesses positioned around emerging trends and scalable growth opportunities.

Hospital Expansion Pipeline

The expansion pipeline is central to the thesis. Park Medi World had commissioned 680 beds and planned another 750 beds in H2FY27, targeting approximately 40 per cent bed-capacity growth in FY27.

  • Management expects a further 1,000 beds across four hospitals in FY28.
  • The Prayagraj PPP project is expected to add 550 beds by December 2028.
  • In total, 2,300 beds under execution are intended to lift capacity from 4,290 beds to 6,590 beds by December 2028.
  • Management reiterated a longer-term ambition of more than 10,000 beds by FY33.

Expansion is expected to be funded through internal accruals, avoiding equity dilution, with capital expenditure intensity of around Rs 30 lakh to Rs 35 lakh per bed.

Management Guidance and Operating Leverage

Management reaffirmed revenue guidance of Rs 2,050 crore for FY27 and Rs 2,550 crore for FY28. It expects elevated consumable costs to ease in Q3FY27 and Q4FY27 as pricing, ARPOB and utilisation improve.

Brownfield hospitals are expected to reach operating breakeven within four to six months, while greenfield hospitals may take 12 to 15 months. Management also targets a payer mix of 70 per cent government schemes and 30 per cent private payers over the next 12 to 18 months, compared with 76 per cent government schemes in Q2FY27.

Management expects the oncology drug trade-margin cap to have negligible profitability impact because of procurement efficiency and the government-insurance business mix.

Estimates and Key Execution Factors

Choice cut its FY27E and FY28E estimates to reflect lower margins during the expansion phase.

Estimate FY27E reduction FY28E reduction
Revenue 7.4% 9.8%
EBITDA 14.4% 13.3%
PAT 24.6% 21.3%

The broker forecasts revenue, EBITDA and PAT CAGRs of 28.0 per cent, 28.0 per cent and 31.4 per cent, respectively, over FY26 to FY29E.

Execution of hospital ramp-ups, occupancy improvement, cost normalisation, payer-mix improvement and realisation of operating leverage are key to the outlook.

Download Original Research Report

Disclaimer: This is a summary of a research report published by the broker/research house identified above. The views, recommendations, target prices and estimates are those of the respective broker and do not represent DSIJ investment advice. The summary may be AI-assisted, hence please refer to the original report for complete details, disclosures and risks.